Cutaneous ulcers following hydroxyurea therapy

Phlebologie ◽  
2004 ◽  
Vol 33 (06) ◽  
pp. 202-205 ◽  
Author(s):  
K. Hartmann ◽  
S. Nagel ◽  
T. Erichsen ◽  
E. Rabe ◽  
K. H. Grips ◽  
...  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Antineoplastic Agent ◽  
Limited Time ◽  
Myeloproliferative Diseases ◽  
Dermatological Side Effects ◽  
Chronic Myeloproliferative Diseases ◽  
Hydroxyurea Therapy

SummaryHydroxyurea (HU) is usually a well tolerated antineoplastic agent and is commonly used in the treatment of chronic myeloproliferative diseases. Dermatological side effects are frequently seen in patients receiving longterm HU therapy. Cutaneous ulcers have been reported occasionally.We report on four patients with cutaneous ulcers whilst on long-term hydroxyurea therapy for myeloproliferative diseases. In all patients we were able to reduce the dose, or stop HU altogether and their ulcers markedly improved. Our observations suggest that cutaneous ulcers should be considered as possible side effect of long-term HU therapy and healing of the ulcers can be achieved not only by cessation of the HU treatment, but also by reducing the dose of hydroxyurea for a limited time.

Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration

2020 ◽  
pp. 107815522097062
Author(s):  
Uğur Çelik ◽  
Ertuğrul H Aydemir ◽  
Burhan Engin ◽  
Muazzez Ç Oba ◽  
Mesut Yılmaz ◽  
...  
Keyword(s):  
Side Effects ◽  
Outpatient Clinic ◽  
Targeted Therapies ◽  
Side Effect ◽  
Common Side Effect ◽  
Cancer Therapies ◽  
Anti Cancer ◽  
Targeted Cancer Therapies ◽  
Dermatological Side Effects ◽  
Skin Side Effects

Introduction Novel anti-cancer drugs such as targeted cancer therapies and immune check-point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this study is to report an overview of the commonly consulted dermatological side effects of ICIs and targeted cancer therapies in clinical practice, along with their management. Methods In this single-center study, we evaluated consecutive oncological patients who were referred from the oncology outpatient clinic to the dermatology outpatient clinic due to skin side effects of ICIs and targeted therapies. All patients were examined and treated at the same day of referral by experienced dermatologists. Patient characteristics, clinical findings, diagnostic workups and treatments were retrieved from outpatient records. Results Sixty three patients were enrolled. Most common diagnoses were lung carcinoma, melanoma and colon carcinoma. Fifty patients (79%) were using targeted therapies while 13 (21%) were using ICIs. Xerosis was the most common side effect (44%), followed by acneiform rash, paronychia, eczema and pruritus. Majority of the side effects were grade 2 and 3. Psoriasis was a common side effect of ICIs. One patient had a newly developed dysplastic nevus on vemurafenib treatment. Oncological treatment was not withheld in any of the patients. Conclusions This study revealed the most commonly consulted skin side effects of novel anti-cancer drugs and their management in daily practice. We underlie the importance of collaborative work of oncology and dermatology professionals as early management of cutaneous side effects of targeted therapies and ICIs improves patient outcomes.

The Initiation of Long-Term Pharmacotherapy in Schizophrenia: Dosage and Side Effect Comparisons Between Oral and Depot Fluphenazine*

1976 ◽  
Vol 09 (04) ◽  
pp. 159-169 ◽  
Author(s):  
Nina R. Schooler ◽  
J. Levine ◽  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Dosage Forms ◽  
The Other ◽  
Oral Drug ◽  
Double Blind ◽  
Moderate Severity ◽  
Treatment Groups ◽  
The Relationship

SummaryThis report focuses on two comparisons between oral and depot fluphenazine specifically FPZ decanoate: 1) can equivalent dosages for the two drugs be established and do these equivalencies change over six months of treatment; 2) what are the side effects seen with the two drugs during the early weeks of administration.Patients in the study receive either oral or depot FPZ as the active treatment but in order to preserve double blind conditions, they are also given the other treatment in placebo form. No dosage equivalence is established by the protocol, however, if dosage is adjusted, both forms must be changed and in the same direction. During the first weeks of treatment there is a linear relationship between the two dosage forms but a range of relatively low dosages of the oral compound (5-20 mg) is associated with a single dose (25 mg/q 3 weeks) of FPZ decanoate. At higher dosages of the oral drug the relationship is linear. Side effects of some kind are noted in over 60 percent of patients in both treatment groups after four weeks of treatment, while symptoms of at least moderate severity occur in almost 40 percent. Only symptoms involving the extrapyramidal system and sleep disturbance are observed in more than 20 percent of the patients. Benztropine was prescribed only if needed and was administered to 65 percent of patients. In general, those receiving benztropine had more side effects than those who did not. These differences reached significance for extrapyramidal symptoms and depression.Based on these data, we conclude that at the dosages used in this study there are no side effect differences between these two forms of fluphenazine in the early weeks of administration. Dosage equivalence between the two drugs can be set within the range of 5- 60 mg/day oral and 12.5-100 mg/three weeks depot.

scholarly journals A comparision of efficacy of risperidone and olanzapine in schizophrenia patients

2012 ◽  
Vol 7 (3) ◽  
pp. 29-35
Author(s):  
SK Shah ◽  
SP Ojha ◽  
NR Koirala ◽  
VD Sharma ◽  
B Yengkokpam
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Drop Out ◽  
Medical Sciences ◽  
Open Label ◽  
General Psychopathology ◽  
Sexual Side Effects ◽  
Significant Difference

Schizophrenia is a leading worldwide mental health problem. It is also one of the common and challenging problems in Nepal. Risperidone and olanzapine is one of the major antipsychotic drug used for schizophrenia patients, however their efficacy is not compared in Nepal.To assess the efficacy of risperidone and olanzapine in schizophrenia patients in Nepalese context. An open-label, randomized, comparative, prospective study was done for 6 weeks. Total of 63 patients attending Psychiatry OPD in Jan to July 2008 at TUTH who could be available for close follow up were enrolled with consent. Risperidone was given in dose of 3-6 mg and Olanzapine in the dose of 15-20 mg per day. Efficacy and tolerability was assessed using PANSS, CGI, and UKU side-effect checklist. Both groups showed improvement in the entire positive, negative and general psychopathology subscales without significant difference in the two groups. Regarding tolerability, olanzapine was found to have significant sedation, weight gain while with risperidone extrapyramidal side-effects, palpitations, sexual side-effects were significant. Risperidone and olanzapine both are efficacious in the treatment of schizophrenia. Both the drugs have their own side-effects. Long-term efficacy and tolerability needs to be studied. As it has been seen in the ongoing studies, long-term use and side-effect profile, drop-out rates and the increase in metabolic syndromes need more consideration.DOI: http://dx.doi.org/10.3126/jcmsn.v7i3.6706 Journal of College of Medical Sciences-Nepal, 2011, Vol-7, No-3, 29-35

The influence of age on lithium efficacy and side-effects in out-patients

1983 ◽  
Vol 13 (1) ◽  
pp. 53-60 ◽  
Author(s):  
N. Murray ◽  
S. Hopwood ◽  
D. J. K. Balfour ◽  
S. Ogston ◽  
D. S. Hewick
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Lithium Treatment ◽  
The Other ◽  
Hand Tremor ◽  
Age Related

SynopsisOne hundred and sixty-six unipolar and bipolar out-patients (21–78 years) on long-term lithium treatment were studied on a prospective basis. Although there was a possible tendency for manic attacks to increase in prevalence and severity with age, it was difficult to demonstrate a general age-related decline in lithium efficacy. There was a tendency for the prevalence and severity of fine hand tremor to increase with age. This was not seen with polydipsia/polyuria, the other typical lithium side-effect.

scholarly journals Levetiracetam Induced Hyperkalemia – A Rare Side Effect in Elderly with Pre-Existing Subclinical Renal Insufficiency Presenting with Bradyarrhythmia

2021 ◽  
pp. 185-190
Author(s):  
Abhishek Chande ◽  
Vidyashree Hulkoti ◽  
Shivam Khanna ◽  
Sunil Kumar
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Case Scenario ◽  
Rare Form ◽  
P Waves ◽  
Generalized Seizures ◽  
Rare Side Effect ◽  
Severe Hyperkalemia ◽  
Term Management

Levetiracetam is a commonly used drug in today’s world for long term management of partial as well as generalized seizures mainly due its major advantage that is has so few and non-threatening side effects[1].In the following case scenario, we show how a 70 years old male presented with severe hyperkalemia and after no other common culprits were seen, it was thought to be a side effect therapy with levetiracetam and after discontinuing it and managing hyperkalemia, the patient’s condition improved from a very critical state. We also show a rare form ECG presentation of severe hyperkalemia in the form of bradyarrhythmia with absent P waves. Our experience shows that unpredictable and rare side effects of new anti-epileptic drugs should be given attention and such cases often go undiagnosed.

Weight gain - a side effect of antidepressive treatment

2011 ◽  
Vol 26 (S2) ◽  
pp. 628-628
Author(s):  
I. Gabos Grecu ◽  
M. Gabos Grecu ◽  
M. Florea ◽  
T. Moica ◽  
M. Ferencz ◽  
...  
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Side Effect ◽  
Sleep Disturbances ◽  
Antidepressant Treatment ◽  
Primary Diagnosis ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Compliance To Treatment

IntroductionLike all medical therapies, antidepressants have several limitations that clinicians should consider when choosing treatments for their patients. [1] Common long-term side effects of antidepressants are weight gain, sexual dysfunction, sleep disturbances, fatigue, apathy, and cognitive impairment. [2] These side effects will influence the quality of life and will be an important factor in determining the compliance to treatment for these patients. [3]AimIs to present a study on weight gain in patients treated long term with antidepressants.Methods: We made a retrospective study of 422 patients with Major Depressive Disorder hospitalized in First Clinic of Psychiatry Tirgu Mures, between Jan/2009 and June/2009. We built the study after patient data on the following criteria: age, sex, place of origin, educational level, occupation, primary diagnosis, BMI at first admission, BMI at the last hospitalization, the average years of treatment, the average hospitalizations and antidepressant treatment applied.ResultsThe vast majority of hospitalized patients were females (71%) in the age group 40-49. In summarizing this side effect of antidepressant treatment, we can say that weight gain is significant for long-term treatment with tricyclic antidepresives (64.38% of patients), tetra cyclic (50.30% of patients) and NaSSA (40% of patients). We found an increase of BMI of about 13.5% in these patients. For the patients treated with SSRIs, NDRI and SNRI we found that weight gain was present in less than 40% of patients and this had also influenced the compliance and the adherence to treatment of these patients.

scholarly journals Chemotherapy-induced peripheral neuropathy: an update on the current understanding

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1466 ◽  
Author(s):  
James Addington ◽  
Miriam Freimer
Keyword(s):  
Nervous System ◽  
Peripheral Neuropathy ◽  
Side Effects ◽  
Side Effect ◽  
Chronic Phase ◽  
Chemotherapeutic Agents ◽  
Common Side Effect ◽  
Targeted Treatments ◽  
Timely Fashion

Chemotherapy-induced peripheral neuropathy is a common side effect of selected chemotherapeutic agents. Previous work has suggested that patients often under report the symptoms of chemotherapy-induced peripheral neuropathy and physicians fail to recognize the presence of such symptoms in a timely fashion. The precise pathophysiology that underlies chemotherapy-induced peripheral neuropathy, in both the acute and the chronic phase, remains complex and appears to be medication specific. Recent work has begun to demonstrate and further clarify potential pathophysiological processes that predispose and, ultimately, lead to the development of chemotherapy-induced peripheral neuropathy. There is increasing evidence that the pathway to neuropathy varies with each agent. With a clearer understanding of how these agents affect the peripheral nervous system, more targeted treatments can be developed in order to optimize treatment and prevent long-term side effects.

A 39-year-old man with a generalized rash with bupropion XL administration

2011 ◽  
Vol 26 (S2) ◽  
pp. 1225-1225
Author(s):  
M.A. Ates ◽  
M. Cetin ◽  
S. Ebrinc ◽  
C. Basoglu ◽  
A. Algul
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Skin Rash ◽  
Side Effect ◽  
Extended Release ◽  
Dry Mouth ◽  
Once Daily ◽  
Cutaneous Side Effect ◽  
Dermatological Side Effects

IntroductionAn once-daily formulation, bupropion XL, was developed with the goal of further improving tolerability and compliance (1). Common adverse effects contain dry mouth, nausea, constipation, headache, agitation and skin rash (2).ObjectiveA case of skin rash caused by bupropion XL used for depression is discussed.ResultsA 39-year-old man with depression developed a rash on his extremities 13 days after the initiation of bupropion XL followed by pruritus of the arms, feet, and face.ConclusionsTo our knowledge, this is the first reported case of skin rash and urticaria induced by bupropion XL therapy. The most common cutaneous side-effect is urticaria and rash by bupropion XL. This develops from between 8 and 21 days after taking the medicine (3). In our case dermatological side effects developed on 13 days. On discontinuation of bupropion XL, there was whole resolution of symptom. We report this case to notify clinicians of the potential dermatological side effects that can occur with extended release bupropion therapy.

scholarly journals Optimising neuroleptic treatment for psychotic illness

1998 ◽  
Vol 22 (9) ◽  
pp. 548-551 ◽  
Author(s):  
Geoffrey Searle
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Antipsychotic Agents ◽  
Neuroleptic Treatment ◽  
Psychotic Illness ◽  
New Compounds

The release of the antipsychotic agents risperidone, sertindole and olanzepine forces difficult choices upon clinicians. The new compounds are better tolerated than neuroleptics, expensive and their long-term side-effects unknown. These choices can be made easier by the dose and side-effect minimisation procedure set out below, which aims to produce the greatest benefit and least harm from conventional neuroleptics.

Sign in / Sign up

Export Citation Format

Share Document